On August 11, 2026, the National Medical Products Administration (NMPA) of China formally approved a new indication for ivonescimab — the world’s first PD-1/VEGF bispecific antibody — for use in combination with paclitaxel and carboplatin as first-line treatment for patients with unresectable locally advanced or metastatic squamous non-small cell lung cancer (NSCLC). This is the third indication approved for ivonescimab, marking its expanding role in the treatment of advanced NSCLC.
Unmet Need: Challenges in First-Line Treatment of Advanced Squamous NSCLC
Lung cancer is the malignancy with the highest incidence and mortality in China, with NSCLC accounting for approximately 80%–85% of cases [1]. Squamous NSCLC, as one of the major subtypes, represents approximately 20%–30% of NSCLC cases [2]. Unlike lung adenocarcinoma, patients with squamous NSCLC have a low rate of targetable driver-gene mutations and have therefore long derived limited benefit from targeted therapies.
For the past eight years, the standard first-line treatment for advanced squamous NSCLC has been a PD-1/PD-L1 inhibitor combined with chemotherapy. However, in pivotal phase 3 trials, PD-1 inhibitor plus chemotherapy regimens have produced median progression-free survival (PFS) of only 5.5 to 8.5 months, suggesting a plateau in efficacy. In addition, conventional anti-angiogenic agents have been limited in lung squamous cell carcinoma because of potential bleeding risk, leaving an unmet need for new therapeutic options.
HARMONi-6: The First Phase 3 Study to Head-to-Head Beat the Current Immuno-Chemotherapy Standard
The approval is based on HARMONi-6 (NCT05840016), a randomized, double-blind, multicenter pivotal phase 3 trial [3]. Its significance lies in the following: it is the first phase 3 study to use the current standard of care (a PD-1 inhibitor plus chemotherapy) as the control and achieve positive results on both PFS and overall survival (OS). Earlier trials in this setting had used chemotherapy alone as the comparator.
A total of 532 patients were enrolled; 92.3% had stage IV disease and 63.2% had central-type squamous tumors. Notably, the study also enrolled patients at high bleeding risk, including those with major vascular involvement, tumor cavitation, or a history of hemoptysis [3] — a population that more closely reflects real-world clinical practice in China. The experimental arm received ivonescimab plus chemotherapy, while the control arm received tislelizumab plus chemotherapy. The primary endpoint was median PFS; OS was a key secondary endpoint with statistical power.
Dual PFS and OS Positivity May Shift First-Line Standard for Advanced Squamous NSCLC
The HARMONi-6 PFS results were first presented at the 2025 ESMO Presidential Symposium, and the OS results were subsequently presented at the 2026 ASCO Annual Meeting; both analyses were published in full in The Lancet [3,4].
Primary Endpoint — PFS: Decisive Superiority
In HARMONi-6, ivonescimab plus chemotherapy achieved a median PFS of 11.1 months, versus 6.9 months in the tislelizumab plus chemotherapy arm (HR=0.60, P<0.0001) — an absolute difference of 4.2 months and a 40% reduction in the risk of disease progression or death [3]. This is, to date, the highest median PFS reported in this setting and represents one of the largest PFS improvements seen in first-line squamous NSCLC trials.
Key Secondary Endpoint — OS: Significant Survival Benefit
In the interim OS analysis, ivonescimab plus chemotherapy achieved a median OS of 27.9 months, compared with 23.7 months for tislelizumab plus chemotherapy (HR=0.66; 95% CI 0.50–0.87; P=0.0017), translating to a 34% reduction in the risk of death [4]. With longer follow-up, the survival benefit has widened: 1-year OS rates were 78.9% vs 72.2% (a 6.7-percentage-point gain), while 2-year OS rates reached 64.7% vs 48.6% (a 16.1-percentage-point gain). Approximately two-thirds of patients in the ivonescimab arm remained alive beyond 2 years, suggesting a long tail of survival benefit with this regimen.
Subgroup Analysis: Consistent Benefit Across Populations
In all key subgroups analyzed, ivonescimab plus chemotherapy showed a consistent OS benefit — regardless of age, PD-L1 expression status (HR=0.64 in PD-L1-negative; HR=0.68 in PD-L1-positive), presence of liver metastases (HR=0.69 with; HR=0.68 without), or number of baseline metastatic sites (HR=0.47 in patients with ≥3 sites) [4].
Addressing an Unmet Need: Manageable Safety Opens the Door to Anti-VEGF Therapy in Squamous NSCLC
Bleeding risk has long been the main barrier to using anti-angiogenic agents in squamous NSCLC. Despite enrolling a population with substantial baseline bleeding risk (central-type tumors 63%, history of hemoptysis 31%, major vascular involvement 18%, tumor cavitation 9% [3]), HARMONi-6 showed an encouraging safety profile.
The ivonescimab plus chemotherapy regimen was generally well tolerated, with no new safety signals identified. The most common grade ≥3 treatment-related adverse events were chemotherapy-related myelosuppressive events. The incidence of immune-related adverse events and grade ≥3 immune-related AEs was comparable to that in the control arm. Grade ≥3 hemorrhage occurred in 2.6% of patients in the ivonescimab arm, comparable to 0.8% in the control arm [4]. These findings provide the first evidence that an anti-VEGF mechanism can be safely applied in squamous NSCLC.
A New Standard May Be Emerging
With positive results on both PFS and OS against the current standard of care, HARMONi-6 suggests that first-line treatment for advanced squamous NSCLC may be shifting from the eight-year “PD-1 plus chemotherapy era.” Each major shift in lung cancer treatment has been marked by a head-to-head win over the prevailing standard. HARMONi-6 is, to date, the first phase 3 study to show such a win on both PFS and OS versus a PD-1 inhibitor plus chemotherapy. The OS positivity presented at this year’s ASCO meeting extends the benefit from PFS to long-term survival, indicating that early disease control translates into durable survival gain. Notably, HARMONi-6 was, according to the article, the first Chinese-originated lung cancer drug study to be featured in an ASCO plenary session in the society’s 61-year history.
Ivonescimab, as the first PD-1/VEGF bispecific antibody, was designed around a “dual-target, single-molecule” concept: one molecule simultaneously binds PD-1 and VEGF with high affinity, achieving synergistic effects of immune checkpoint inhibition and anti-angiogenesis. Through tumor-enriched distribution and Fc-silencing design, the molecule aims to maximize tumor killing while minimizing systemic toxicity.
Across squamous NSCLC, non-squamous NSCLC, and NSCLC after EGFR-TKI resistance, ivonescimab — alone or with chemotherapy — has emerged as the only regimen shown in head-to-head phase 3 trials to outperform the current standard of care.
Conclusion
The approval of ivonescimab plus chemotherapy for first-line treatment of advanced squamous NSCLC represents a notable advance for both drug development and China’s contribution to international clinical research. The HARMONi series of trials is ongoing, and ivonescimab-based combinations may continue to expand the therapeutic options for patients with advanced lung cancer.
References
[1] Bray F, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229–63.
[2] Wang Y, et al. Immunotherapy for advanced-stage squamous cell lung cancer: the state of the art and outstanding questions. Nat Rev Clin Oncol. 2025;22:200–14.
[3] Chen Z, et al. Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial. Lancet. 2025 Nov 1;406(10515):2078–2088.
[4] Lu S, et al. Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in China. Lancet. 2026 Jun 27;407(10548):2620–2629.